The knockdown of RPS6, along with p-RPS6 alterations, induces cell cycle arrest at G0/G1 phase especially through the abnormal regulation of AKT2/mTOR/p70S6K signaling pathway suggesting that targeting RPS6 could be an effective therapy for NSCLC [125]. Here, RPS6 is linked to non-small cell lung carcinoma.